Skip to main content

Table 1 Input parameters used in the model

From: Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program

         Variable

Mean (SE)

Sources

Clinical Variable (Transitional Probability)

RI-HSCT

Q1 state --> Death

Vary

Cohort, MOPH [10]

Q1 state --> BT-ICT

0.00003

Cohort

Q2 state --> Death

Vary

Cohort, MOPH [10]

Q2 state --> BT-ICT

0.0003

Cohort

Q3 state --> Death

Age-specific Mortality

MOPH [10]

Q3 state --> BT-ICT

0.00

Assumption

Q4 state --> Death

Age-specific Mortality

MOPH [10]

Q4 state --> BT-ICT

0.00

Assumption

Iron chelation state --> Death

Age-specific Mortality

MOPH [10]

Iron chelation state--> BT-ICT

0.00

Assumption

Post RI-HSCT --> Death

Age-specific Mortality

MOPH [10]

Post RI-HSCT--> BT-ICT

0.00

Assumption

BT-ICT (Severe Thalassemia patients)

BT-ICT Thal --> BT-ICT Thal with cardiac

0.0114

Borgna-Pignatti C et al.[11]

BT-ICT Thal --> Death

Vary

MOPH [10], Delea et al. [12], Gabutti & Piga [13]

BT-ICT Thal with cardiac --> Death

Vary

MOPH [10] and Chouliaras G [14]

Cost Variable (convert to US $) *,!

RI-HSCT

  

Pre-BMT

  

Direct Medical Cost

1,330 (438)

Hospital Database#

Direct Non Medical Cost

75 (21)

Survey

Indirect Cost

175 (42)

Survey

Q1 state

  

Direct Medical Cost

1,226 (169)

Hospital Database#

Direct Non Medical Cost

458 (51)

Survey

Indirect Cost

945 (105)

Survey

Q2 state

  

Direct Medical Cost

1,710 (381)

Hospital Database#

Direct Non Medical Cost

335 (41)

Survey

Indirect Cost

691 (85)

Survey

Q3 state

  

Direct Medical Cost

1,628 (538)

Hospital Database#

Direct Non Medical Cost

259 (30)

Survey

Indirect Cost

535 (62)

Survey

Q4 state

  

Direct Medical Cost

878 (282)

Hospital Database#

Direct Non Medical Cost

253 (32)

Survey

Indirect Cost

522 (66)

Survey

Iron chelation state

  

Direct Medical Cost

1,120 (238)

Hospital Database#

Direct Non Medical Cost

539 (112)

Survey

Indirect Cost

1,111 (230)

Survey

Post RI-HSCT state

  

Direct Non Medical Cost

1,548 (411)

Hospital Database#

Direct non Medical Cost

299 (146

Survey

Indirect Cost

617 (301)

Survey

BT-ICT (Severe Thalassemia patients)

Severe thalassemia patients without cardiac complications

  

Direct Medical Cost

1,187 (137)

Riewpariboon et al. [28]

Direct Non Medical Cost

1,240 (232)

Leelahavaring et al. [29]

Indirect Cost

636 (221)

Leelahavaring et al. [29]

Severe thalassemia patients with cardiac complications

  

Direct Medical Cost

1,187 (137)

Riewpariboon et al. [28]

Direct Non Medical Cost

1,240 (232)

Leelahavaring et al. [29]

Indirect Cost

636 (221)

Leelahavaring et al. [29]

Effectiveness Variable

  

RI-HSCT

  

Q1 state

0.59 (0.30)

Survey

Q2 state

0.59 (0.30)

Survey

Q3 state

0.59 (0.30)

Survey

Q4 state

0.59 (0.30)

Survey

Iron chelation state

0.88 (0.06)

Survey

Post-RI-HSCT

0.90 (0.05)

Survey

BT-ICT (Severe Thalassemia patients)

  

Severe thalassemia patients without cardiac complications

0.61 (0.03)

Osborne et al. [33]

Severe thalassemia patients with cardiac complications

0.46 (0.02)

Osborne et al. [33]

  1. RI-HSCT: Reduced intensity hematopoietic stem cell, BT-ICT: Blood transfusion combined with subcutaneous iron chelating therapy, Pre-BMT: Pre-bone marrow transplantation.
  2. * ($US, year 2011 value).
  3. # Charges were converted to cost using a cost-to-charge ratio of 1.37 which was derived from Ramathibodi hospital for base-case analysis and 0.8-1.5 [27] for sensitivity analysis.
  4. ! Costs in Q1-Q4 is calculated for 3 month period, while costs beyond Q4 are on an annual basis.